TP53 is a Mutational Target in Non Small Cell Lung Cancer Patients and its Pro/Pro Variant is Potentially Contributing to Cancer Susceptibility

Saxena Alpana^1*, Javid J¹, Mir R¹, Masroor M¹, Ahamad I¹, Farooq S¹, Yadav P¹, Zuberi M¹, Ajaz Ah Bhat², Ahmad I³, Khalanin T⁴, Julka PK⁵, Mohan A⁶, Lone M⁷, Banday MA⁸ and Ray PC¹

¹Molecular Oncology Lab, Department of Biochemistry, Maulana Azad Medical College and Associated hospitals, New Delhi, India

²Division of Surgical Oncology, Vanderbilt University, Nashville, TN, USA

³King Fahd Medical Research Center, King Abdulaziz University, Kingdom of Saudi Arabia

⁴Department of Medicine, BCM, Texas, USA

⁵Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi, India

⁶Department of Medicine, All India Institute of Medical Sciences, New Delhi, India

⁷Department of Radiation Oncology, SKIMS, Srinagar, India

⁸Department of Medical Oncology, SKIMS, Srinagar, India